Navigation Links
Vascular Designs, Inc. Receives CE Mark Approval for Its IsoFlow™ Infusion Catheter to Target Cancerous Tumors
Date:11/14/2011

SAN JOSE, Calif., Nov. 14, 2011 /PRNewswire/ -- Vascular Designs, Inc., a medical device manufacturing company, today announced that its IsoFlow™ Infusion Catheter has received CE Mark approval for use in Europe and Canada. The IsoFlow™ Infusion Catheter enables targeted sideways perfusion, allowing physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With IsoFlow™ Infusion Catheter's unique design, medications can be delivered into areas that could not previously be treated directly, for instance, a cancerous tumor. The device also facilitates the LACE™ (Lateral Arterial Chemo Embolization) procedure.

(Logo: http://photos.prnewswire.com/prnh/20111114/SF06426LOGO)

"CE Mark approval is an important confirmation of the substantial benefits that patients will receive from targeted treatment of cancerous tumors," said Robert Goldman, CEO of Vascular Designs, Inc. and creator of the IsoFlow Infusion Catheter. "Directing treatment to specific locations increases the number of treatment options allowing better access to tumors and may reduce the discomfort to patients associated with the systemic application of chemotherapy."

About Vascular Designs, Inc.

Vascular Designs, Inc. is a medical device company located in San Jose, California. Founder Robert Goldman developed the idea behind Vascular Designs and its innovative IsoFlow™ Infusion Catheter. His personal experience of watching loved ones suffer from, and succumb to cancer, had a profound influence on the creation of IsoFlow.

With the IsoFlow Infusion Catheter's unique design, medications can be pushed into areas that could not previously be treated directly. According to numerous studies, this type of approach to delivery can increase drug concentrations at targeted sites while reducing systemic exposure, potentially improving treatment outcomes.

The IsoFlow Infusion Catheter is in use in hospitals throughout the United States.

For more information on Vascular Designs, Inc., please visit www.vasculardesigns.com.

To view an animation illustrating the IsoFlow Infusion Catheter in action and other press materials, please visit http://www.vasculardesigns.com/news.htm.

Media Contact: Dan Orloff, Orloff Williams Partners, San Jose, 408-202-3188, dorloff@orloffwilliams.com


'/>"/>
SOURCE Vascular Designs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
2. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
3. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
4. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
5. Cardiologists Tackle Next Frontier in Cardiovascular Disease
6. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
7. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
8. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
9. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
10. Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease
11. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, ... continuation of its strategic partnership with and platinum sponsorship of Global Spine Outreach ... safe and effective management of complex spine deformity cases, particularly in children. , ...
(Date:4/24/2017)... ... 2017 , ... Michael Vick announced his retirement earlier this year from the ... number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made four ... most career rushing yards by a quarterback (6,109) and the most rushing yards by ...
(Date:4/24/2017)... ... 24, 2017 , ... As part of the nationwide Days of Remembrance effort ... the Holocaust and Nazi persecution, Center for Medicine after the Holocaust (CMATH) ... Champions trip to Germany and Poland next week. , The Fourth Biennial CMATH Champions ...
(Date:4/24/2017)... ... 2017 , ... Today, Bright Pink , a national non-profit organization focusing on the prevention ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive ... role as Chairman of the Board and launched a national search to find a ...
(Date:4/24/2017)... ... ... Veteran Theresa James awoke to the sound of her newly ex-husband breaking ... James depicts every parent’s worst nightmare, when her three children were violently taken from ... throughout my divorce,” James said. “After the death of my children, I continued to ...
Breaking Medicine News(10 mins):